Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Short term Debt (2017 - 2023)

Sutro Biopharma's Short term Debt history spans 6 years, with the latest figure at $4.1 million for Q4 2023.

  • On a quarterly basis, Short term Debt fell 67.51% to $4.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $4.1 million, a 67.51% decrease, with the full-year FY2023 number at $4.1 million, down 67.51% from a year prior.
  • Short term Debt hit $4.1 million in Q4 2023 for Sutro Biopharma, down from $7.1 million in the prior quarter.
  • Over the last five years, Short term Debt for STRO hit a ceiling of $13.2 million in Q1 2023 and a floor of $1.0 million in Q4 2019.
  • Historically, Short term Debt has averaged $8.1 million across 4 years, with a median of $7.1 million in 2023.
  • Biggest five-year swings in Short term Debt: plummeted 78.83% in 2019 and later soared 300.0% in 2022.
  • Tracing STRO's Short term Debt over 4 years: stood at $1.0 million in 2019, then surged by 837.5% to $9.4 million in 2021, then soared by 33.33% to $12.5 million in 2022, then plummeted by 67.51% to $4.1 million in 2023.
  • Business Quant data shows Short term Debt for STRO at $4.1 million in Q4 2023, $7.1 million in Q3 2023, and $10.2 million in Q2 2023.